An investigational PCSK9 inhibitor with a different mechanism from existing drugs in this class has been shown to safely and ...

In a phase 2b study, treatment with a once-daily oral PCSK9 inhibitor added to statin therapy resulted in a more than 50% ...

Familial hypercholesterolemia results from gene mutations approximately halving the number of functional LDL receptors in heterozygotes and a greater lack in homozygotes. Reduced receptor-mediated ...

Norwitz’s LDL levels dropped by 2 percent in the first ... which combines to a receptor on the liver that inhibits ...

By Vijay Kumar Malesu Study deciphers the molecular handshake between LDL receptors and apoB100, shedding light on cholesterol metabolism and its role in cardiovascular disease. Study: Structure of ...

Vect-Horus has demonstrated how small peptides that target the low-density lipoprotein (LDL) receptor can be coupled with drugs and transported across the BBB 1. More recently, the company has ...

AstraZeneca’s AZD0780 is an investigational oral medication that was developed to lower low-density lipoprotein cholesterol (LDL-C ... not affect the PCSK9-LDL receptor (LDLR) interaction.